Ethylnaphthylaminopropane (ENAP; developmental code name PAL-1045) is a monoamine releasing agent (MRA) of the amphetamine and naphthylaminopropane families that is related to naphthylaminopropane (NAP; PAL-287) and methamnetamine (MNAP; PAL-1046). It acts specifically as a serotonin–norepinephrine–dopamine releasing agent (SNDRA). However, ENAP is unusual in being a partial releaser of serotonin and dopamine and a full releaser of norepinephrine.

The EC₅₀Tooltip half-maximal effective concentration (E_maxTooltip maximal efficacy) values of ENAP in terms of monoamine release induction are 12 nM (66%) for serotonin, 46 nM (78%) for dopamine, and 137 nM (94%) for norepinephrine in rat brain synaptosomes. In contrast to NAP and MNAP, which produce clearly dose-dependent increases in locomotor stimulation and brain monoamine levels in rodents, ENAP has been found to show attenuated monoamine elevations and a "flat" dose–response curve. Relatedly, it may have less misuse liability than other drugs like amphetamine, although more research is necessary to assess this possibility.

In addition to its MRA activity, ENAP has been found to be an effective pharmacological chaperone for rescuing misfolded mutant monoamine transporters (MATs).